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In the19th century, the medical profession used
cannabis preparations to treat pain, convulsions, spasm,
and nausea, and induce sleep [1-3]. Medical use of
cannabis declined in the early 20th century with the ad-
vent of analgesics that could be delivered in better stan-
dardized doses than oral cannabis preparations [3]. This
decline was accelerated by the signing of international
drug control treaties in the 20th century that classed
cannabis as a drug with no medical use. 
There was renewed interest in the medical use of
cannabis in the 1970s in the United States. This occurred
in the midst of rising recreational cannabis use among
young people, ensuring that the debate about the medical
use of cannabis would become entangled in the debate
about whether its recreational use should be permitted
[4]. This entanglement has made it difficult to allow pa-
tients to use cannabis preparations, polarized expert and
lay opinions on whether cannabis has any medical uses,
and made it difficult to conduct clinical trials of the ef-
fectiveness and safety of cannabinoids and cannabis. 
The purpose of this paper is to briefly describe U.S.
policy responses to calls for patients to be allowed to use
the prohibited drug cannabis for medical purposes. The
U.S. medical cannabis debate has produced a variety of
different medical cannabis schemes that have been imple-
mented in around half of the states over the past 40 years.
These schemes also have been internationally influential in
prompting other countries (e.g., Canada, Israel, and the
Netherlands) to allow access to cannabis for medical uses. 
The paper begins by reviewing the evidence on the
efficacy and safety of cannabis and its constituents when
used for a variety of medical purposes (namely, control-
ling nausea and vomiting, stimulating appetite, control-
ling neuropathic pain and muscle spasm in multiple
sclerosis, and treating intractable epilepsy). It then de-
scribes medical marijuana referenda and the schemes that
these have produced in different states. I argue that states
that have liberally defined criteria for medical cannabis
use and allowed commercial supply of cannabis to ap-
proved patients, as exemplified in California, have cre-
ated de facto legal access to cannabis for recreational use.
I end by outlining the type of evidence that is required
for better based policies toward the use of cannabis and
its constituents for medical purposes. 
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REVIEW
This paper discusses the evolution of U.S. policy responses to calls to allow patients to use cannabis for
medical purposes. It first summarizes the research evidence on the safety and efficacy of cannabinoids for
various medical uses. It then outlines the challenges in developing new pharmaceutical cannabinoids that
are safe, effective, and acceptable to patients. It briefly describes the strengths and limitations of the differ-
ent ways in which U.S. states have allowed patients to use cannabis for medical purposes. These include al-
lowing access for research trials only, allowing medical necessity as a defense against prosecution, and
allowing commercial medical dispensaries to provide cannabis to approved patients. It argues that liberal
definitions of indications for medical cannabis use and the commercialization of medical cannabis supply
in California have produced the de facto legalization of recreational cannabis use.
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DO CANNABIS AND ITS CONSTITUENTS HAVE
MEDICAL USES?
In this paper, cannabis refers to products of the
cannabis sativa plant, such as marijuana (the flowering tops
of the plant) and hash (compressed resin), which are usually
smoked by both recreational and medical cannabis users
[5]. The principal psychoactive ingredient of the cannabis
plant is tetrahydrocannabinol (THC†), which acts on spe-
cific receptors in the brain, known as cannabinoid or CB1
receptors. These receptors also respond to a naturally oc-
curring cannabinoid in the brain called anandamide [6]. 
The term cannabinoids is used to describe pharma-
ceutical drugs that act on the brain’s cannabinoid system.
These can be derived from the cannabis plant or chemi-
cally synthesized. If they produce similar psychoactive ef-
fects to THC, they are called cannabinoid agonists [6,7]. 
Medicinal cannabis extracts are standardized prepa-
rations of the cannabis plant that deliver defined standard
doses of cannabinoids. For example, nabiximols (trade
name Sativex) is a cannabis extract produced by combin-
ing equal amounts of extracts from two cloned cannabis
plants that produce high levels of THC and cannabidiol
(CBD), respectively. CBD is a cannabinoid that has few
psychoactive effects, but it appears to moderate the psy-
choactive effects of THC that some patients find unpleas-
ant [8]. Sativex is delivered as an oral sublingual spray to
provide patients with defined doses of THC and CBD
without the patients having to smoke cannabis [8]. 
Indications for Medical Cannabis Use
Advocates claim that cannabis and cannabinoids can
be used to treat nausea and vomiting as side effects of can-
cer treatment; poor appetite in patients with AIDS-related
wasting; chronic pain and painful spasms in multiple scle-
rosis; epileptic convulsions; and glaucoma [6-10]. In each
of these indications, they are used as an adjunctive or sec-
ond-line treatment. Adjunctive treatments are those used
in combination with other medical treatments, while sec-
ond-line treatments are those reserved for patients in
whom standard treatments have proven ineffective or have
been poorly tolerated because of side effects [7]. The fol-
lowing sections outline the medical indications for which
there is some evidence from clinical trials and a biologi-
cally plausible rationale for medical use. The focus is on
evidence from controlled clinical trials, independent sys-
tematic reviews where available from the Cochrane Col-
laboration, and the Institute of Medicine.
Cannabinoids as Antiemetics
In the 1970s and 1980s, controlled clinical trials
found that THC was more effective in treating nausea pro-
duced by cancer chemotherapy and radiotherapy than ei-
ther placebo or the antiemetic drugs in common use
[3,7,11,12]. These studies were done decades ago, many of
the trials were small, and there are now much more effec-
tive antiemetic agents than drugs with which cannabinoids
were compared [7,13]. The antiemetic effects of cannabi-
noids and these newer drugs have not been directly com-
pared, but indirect comparisons indicate that the newer
agents achieve complete control of nausea in 90 percent of
patients, whereas cannabinoids achieved complete control
in only 30 percent of patients [7,13]. This evidence indi-
cates that cannabinoids are not a first-line treatment for
nausea and vomiting in cancer patients, but they still may
be adjunctive or second-line treatments [7,9].
Appetite Stimulation 
Dronabinol (Marinol) was registered in the United
States as an appetite stimulant in patients with terminal
cancer and AIDS-related wasting in the early 1990s on
the basis of several small-scale clinical trials [11]. A
Cochrane review of these studies concluded that the evi-
dence was too weak to draw any conclusions about effi-
cacy or safety [14]. The use of cannabinoids to stimulate
appetite in AIDS patients largely has been obviated by
the advent of highly effective anti-retroviral drugs that
prevent most HIV-infected persons from developing
AIDS-related wasting. 
Neuropathic Pain and Spasticity in Multiple Sclerosis 
Analgesia is one of the oldest reasons for medical
cannabis use [15]. THC and other cannabinoid agonists
act on similar pathways to the opioids but produce anal-
gesia via distinct mechanisms. This suggests that the anal-
gesic effects of combining opioids and cannabinoids could
be larger than the sum of their individual analgesic effects
[16]. In double-blind and placebo-controlled clinical trials,
cannabinoids produce moderate analgesia equivalent to
moderate doses of codeine [7,17]. 
The role of cannabinoids in controlling neuropathic
pain has been evaluated in clinical trials in patients with
multiple sclerosis (MS) [18]. In these trials, patients given
Sativex reported greater subjective relief of painful mus-
cle spasms than patients who received placebo. There
were, however, only marginal reductions in observer rat-
ings of muscle spasm after 3 weeks of treatment [19].
Larger reductions were reported in observer ratings and
patient reports of spasticity and pain in a 12-month fol-
low-up of the subset of these patients who continued to
use cannabinoids for over a year [20]. A meta-analysis of
the controlled trials (involving 298 patients) [21] found
that Sativex produced a larger reduction in pain (1.5 ver-
sus 0.8 points on a 10-point rating scale) than placebo after
3 weeks of treatment [21]. This improvement was less
than that defined as “clinically significant” (2 points). 
A recent review of studies of nabiximols (Sativex) in
MS [18] concluded that most have shown a greater re-
duction in symptoms of spasticity in patients receiving
Sativex than in those on placebo. The adverse effects were
also generally mild to moderate, with the most common
being dizziness, diarrhea, fatigue, nausea, headache, and
somnolence. Podda and Constaninescu emphasized that
Sativex was added to more traditional anti-spasticity drugs
rather than being used as a stand-alone treatment [18]. 
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Epilepsy 
Cannabidiol (CBD) has anti-convulsant effects in an-
imal models of epilepsy [22]. Four small randomized,
placebo-controlled trials of CBD have been conducted on
patients whose epilepsy had not responded to first-line
anti-convulsants. CBD was given in addition to their usual
anti-convulsant drugs [23]. The studies were small, and,
according to a Cochrane review, their results were incon-
clusive [24]. 
There has been recent clinical interest in using CBD
to treat Dravet’s syndrome, the childhood epilepsy syn-
drome. Epilepsy in Dravet’s syndrome does not respond to
conventional anti-convulsants and can produce severe in-
tellectual disability and death if untreated. Some parents
have reported that cannabis extracts with high levels of
CBD have controlled or greatly improved their children’s
epilepsy. Randomized, controlled clinical trials are pro-
posed to test the therapeutic effects of CBD [25,26].
WHAT ARE THE RISKS OF MEDICAL 
CANNABINOID USE?
Risks of Short-Term Use
Wang et al. [27] conducted a meta-analytic review of
the adverse effects in randomized controlled trials (RCT)
of cannabinoids and cannabis extracts. They found that 97
percent of the adverse effects in the clinical trials were
minor, with dizziness (20 percent) being the most com-
mon. They did not find a higher rate of serious adverse
events in patients given cannabinoid drugs (either as plant
extracts or THC preparations) than in those given placebo.
Wang et al.’s conclusions agree with the Institute of Med-
icine [7], which concluded that the acute adverse effects of
cannabinoids were “within the risks tolerated for many
medications” and patients would develop tolerance to
these effects with continued use. 
The Risks of Longer-Term Use in Chronic Diseases
Wang et al. [27] were unable to evaluate the risks of
longer-term medical use of cannabinoids (e.g., used to
treat multiple sclerosis) because the clinical trials have all
been short-term (from 8 hours to 12 months). 
A small number of studies have been done on the
emotional and cognitive effects of long-term Sativex use
in patients with MS. In one study, patients who received
Sativex for 50 weeks reported no statistically significant
differences from placebo on cognitive and mood tests
[28]. Participants in another RCT did not show any per-
formance differences in the Paced Auditory Serial Addi-
tion Test or score differences in the Beck Depression
Inventory [29]. Larger studies of this type need to be con-
ducted over periods of years to assess the safety of long-
term medical use of cannabinoids.
Population-based studies of recreational cannabis
users provide indications of the possible adverse effects
of long-term cannabis use that should be examined in
longer-term clinical studies. These studies have examined
the effects in adolescence and early adulthood of regular
(usually daily) and sustained cannabis smoking by young
people and, less commonly, the risks of long-term health
harms, such as cancers, that may arise from exposure to
carcinogens in cannabis smoke over decades [5,30]. 
Recreational users who use daily can become de-
pendent on cannabis [31]. The risk is higher if they begin
smoking cannabis in adolescence and smoke the most po-
tent cannabis products daily during young adulthood [32].
A substantial minority of cannabis-dependent persons seek
help to stop using cannabis [5]. The risks of dependence
are probably higher in recreational users who smoke po-
tent forms of cannabis multiple times per day than they
are in older adults who use smaller oral doses of cannabi-
noids for symptomatic relief [4]. There is nonetheless
some evidence that patients taking Sativex daily over a
period of months experience withdrawal symptoms when
they cease using the drug [33]. It is uncertain how many
of these patients will develop a full dependence syndrome
or experience difficulty in ceasing their use. We need stud-
ies of the risks and consequences of cannabis dependence
in long-term medical cannabis or cannabinoid users to see
if this is the case. 
Longitudinal studies of young adults also suggest that
daily cannabis can precipitate psychotic symptoms and
disorders in individuals with a personal or family history
of these disorders [34,35]. Again, this evidence comes
from studies of young adults who started daily cannabis
use in adolescence and used regularly throughout young
adulthood, the period when the risk of developing psy-
chotic disorders is at its highest. The Australian Thera-
peutic Goods Administration (TGA) has noted with
concern reports of acute psychotic syndromes in patients
given Sativex [33], as well as the abovementioned evi-
dence that some patients develop dependence [33]. Given
these reports, it would be prudent to advise persons with
a personal or family history of psychosis to either avoid
using cannabis for medical purposes or use it with care
and monitor adverse psychological effects [36].
The cardiovascular risks of cannabinoid use are of
greater potential concern to medical cannabis users. The
risks of cardiovascular disease are higher among older
adults than among younger recreational users [37], and
there are epidemiological studies suggesting that cannabis
smoking can precipitate myocardial infarction in older
adults [5]. There are also a number of case reports of se-
rious cardiovascular complications, including cardiac
deaths, in young recreational cannabis users [38,39]. It
would be prudent for older patients to avoid smoking
cannabis and use oral cannabinoids or cannabis extracts. 
The cancer risks of long-term cannabis smoking are
unclear because studies have produced inconsistent find-
ings, and in many of these studies, it has been difficult to
separate the effects of cannabis smoking from those of to-
bacco smoking because most cannabis smokers have also
smoked tobacco [5,40]. The cancer risks of cannabis use
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may be of little concern to older patients with a limited
life expectancy, such as those with terminal cancer. They
may be of more concern in patients with MS or chronic
pain, who may use cannabis daily over years and possi-
bly decades. Again, it would be prudent for long-term
medical cannabis users to avoid smoking cannabis and use
oral cannabinoids or cannabis extracts. 
HOW CAN WE MAKE PHARMACEUTICAL
CANNABINOIDS AVAILABLE FOR MEDICAL
USE?
A synthetic form of THC, dronabinol, was registered
for medical use as an antiemetic and appetite stimulant in
the United States in 1985. Nabilone, a synthetic cannabi-
noid with similar effects to THC, was approved for use in
AIDS-related wasting in 1992. But neither of these drugs
has been widely used because patients have found it diffi-
cult to obtain therapeutic doses that did not also produce
unwanted adverse side effects [7,41]. This largely reflects
the drawbacks of using the oral route to take THC. When
taken orally, THC has a delayed onset of effect and patients
either receive insufficient THC for therapeutic benefit or
too much and experience adverse side effects [6,41]. 
Pharmaceutical companies have not developed better
cannabinoids than dronabinol and nabilone for a number of
reasons. First, it is costly to develop and test new cannabi-
noids [7] and difficult to recoup these costs when the indi-
cations for their medical uses are uncommon and more
effective drugs have been developed for nausea and vom-
iting [7,42]. Second, regulations controlling the medical
use of prohibited substances make it difficult to conduct
basic and clinical research on drugs that are chemically
similar to or derived from a prohibited drug. Third, these
regulations also impose restrictions on medical use of any
cannabinoids that may be approved for human use, thereby
discouraging physicians from using them [4,7,43]. 
Cannabis extracts such as Sativex have been trialled
in the United Kingdom [6,8], with considerable support
from U.K. pharmaceutical regulatory authorities [44].
U.K. manufacturers of Sativex (Guy Pharmaceuticals)
have patented the processes used to produce Sativex
(rather than its natural constituents THC and CBD). After
controlled clinical trials, Sativex has been approved for
use in patients with MS in Canada, Czech Republic, Den-
mark, Germany, New Zealand, Spain, Sweden, and the
United Kingdom [45]. Sativex has been approved for clin-
ical use in the United Kingdom, but it has not been ap-
proved for publicly subsidized use under the National
Health System. It has not yet been approved in the United
States, and it remains to be seen if Sativex (and other
cannabis extracts) are more acceptable to patients than
dronabinol and nabilone have been. 
Allowing the Medical Use of Cannabis Products
The lack of acceptable pharmaceutical cannabinoids
and the restricted research access schemes prompted some
U.S. advocates of medical cannabis use to campaign for
state laws that would allow patients to smoke cannabis for
medical reasons. According to surveys, “medical mari-
juana” enjoys majority support in the U.S. population, and
this has been reflected in the passage of referenda in
around half of the U.S. states that allow the use of mari-
juana for medical purposes [46]. The challenge for U.S.
state governments in responding to these calls has been in
finding ways to allow patients to access cannabis products
for medical use while recreational cannabis use has re-
mained illegal. 
MEDICAL MARIJUANA INITIATIVES IN THE
UNITED STATES
Compassionate Access Schemes and Medical 
Necessity Defenses
Between 1975 and 1992, the U.S. government al-
lowed patients with a restricted list of medical conditions
to have compassionate access to cannabis under the In-
vestigational New Drug (IND) program [47]. Eight U.S.
states legislated to allow the medical use of cannabis under
similar conditions, but only a very small numbers of pa-
tients were able to access cannabis for medical purposes
under these schemes, and the Reagan administration re-
fused to allow new patients to enter the scheme after the
1970s [47]. 
Some states have allowed “medical necessity” as a
defense against prosecution for using cannabis to treat
symptoms of serious illnesses [47]. This approach has pro-
vided guidance to police in deciding whether to prosecute
patients who have defined medical conditions but who
were left to obtain cannabis from the illegal market in the
absence of legal medical supply.
Medical Marijuana Referenda
Because of the restrictiveness of the federal IND pro-
gram and lack of access to cannabis under states that al-
lowed a medical necessity defense, medical marijuana
advocates in the 1990s campaigned to pass citizen-initi-
ated referenda that would allow patients to use cannabis
for medical purposes. In 1996, Californian voters passed
Proposition 215 (by 56 percent to 44 percent). This al-
lowed patients to use marijuana for a broad set of medical
indications that included those supported by evidence
(namely, nausea, weight loss, pain, and muscle spasm). It
also allowed medical use under an open-ended category,
namely, any “serious medical condition.” This term was
not well defined but left to the discretion of a medical
practitioner who decided whether a patient had an illness
serious enough that could only be relieved by their using
marijuana [48]. 
Since 1996, a total of 23 U.S. states have legislated to
allow the medical use of marijuana. This has been done
either by passing a referendum proposal or at the initia-
tive of the legislature [49]. Not all these state schemes
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allow access to marijuana for medical purposes in the
same liberal fashion as California. State medical cannabis
laws and regulations vary in how many and what type of
patients they allow to use marijuana and the conditions
under which they are allowed to obtain the drug [50]. 
The approved indications for medical use vary from
very narrow to the very broad [50]. Some states define
medical use as the use of cannabis to treat only indications
for which there is evidence of efficacy from controlled tri-
als (i.e., nausea in cancer, appetite stimulation in AIDS,
and analgesia). A few states have followed California’s
example in defining a broadly inclusive set of indications
that allow medical use for any condition that a physician
believes may benefit from the use of marijuana [51-53].
States also differ in whether they require physicians to ex-
amine a patient, advise them about the risks of using mar-
ijuana, and monitor the health of patients who use
marijuana [52]. 
Prescriber Conundrums
Medical marijuana schemes create problems for pre-
scribers. Laws allowing physicians to prescribe cannabis
conflict with U.S. federal law, which does not allow the
use of cannabis for any purpose. Under the U.S. Consti-
tution, federal laws pre-empt state laws [4,48]. The Bush
administration threatened to strip doctors of their licenses
to practice if they recommended marijuana to their pa-
tients. Even when the U.S. courts removed this threat,
physicians remained reluctant to recommend cannabis be-
cause of concerns that they would be legally liable for any
harms experienced by their patients [47,51]. In the ab-
sence of data, physicians also found it difficult to decide
to whom they should recommend cannabis, in what
amounts, and for how long [54,55]. These challenges have
been ignored by a small number of physicians, who ad-
vertised their preparedness to provide patients with a med-
ical recommendation for a fee.
Obtaining Medical Cannabis
In 2001, the U.S. Supreme Court ruled that persons
who supplied cannabis for medical use were not protected
from federal criminal prosecution by state laws that al-
lowed medical marijuana use [4]. Patients either had to
secure their cannabis from the black market or, in some
states, were allowed to grow cannabis for their own med-
ical use or have a carer grow it on their behalf. The Bush
administration enforced federal laws against cannabis cul-
tivation and supply in medical marijuana states, but in
2009, the Obama administration indicated that it would
refrain from doing so [51]. 
The Obama administration enforced federal laws
against the large-scale commercial cultivation of cannabis,
but it tolerated commercial cannabis “dispensaries,” pro-
vided that they only sold marijuana to patients who had a
doctor’s letter of recommendation [56]. The number of
dispensaries increased rapidly in California, Colorado, and
Washington State after the 2009 decision. The dispensaries
were not licensed to produce cannabis and so had to obtain
it from the illicit market [51], creating a quasi-legal
cannabis distribution system. The combination of a com-
mercial cannabis supply system and very liberal criteria
for what constituted medical cannabis use effectively al-
lowed recreational users to obtain and use cannabis with-
out fear of prosecution, provided that they had a doctor’s
letter recommending that they use it for medical reasons
[52,53,57]. 
Studies of the characteristics of approved medical
marijuana users in California indicate that substantial
numbers of recreational users have accessed cannabis via
medical cannabis dispensaries. A survey of 4,117 patients
in the San Francisco Bay Area in 2001-2007 reported that
77 percent were male with an average age of 32 years.
Most (89 percent) had started using cannabis before the
age of 19, and 90 percent were daily smokers who used
between an eighth and a quarter of an ounce per week
[58]. There were no data on the medical indications for
which they used cannabis. Similar results emerged in an-
other survey of 1,746 medical marijuana patients in Cali-
fornia in 2006: three quarters were male, only 13 percent
were older than 55 years, and two-thirds were daily smok-
ers and had been so since adolescence [59]. 
A survey of self-reported “medical marijuana use” in
a representative sample of the Californian population con-
firms the findings on dispensary clients [60]. In total, 7
percent of Californian adults reported “medical cannabis
use.” The highest rate of self-reported medical use was
among adults aged 18-24 years (10 percent). The lowest
rate (1.5 percent) was among persons over the age of 65
years, the age group in which one would expect to find
more persons with cancers, neurological disorders, and
chronic pain. These findings indicate that there is a
“porous boundary” between recreational and medical
cannabis use in California [4,52,53,59]. 
Some may argue that the high rates of use in Califor-
nia reflect the use of cannabis to self-medicate anxiety and
depression. The self-medication of depression is indeed a
common reason for young people begin using alcohol and
cannabis [61]. Initially, use of cannabis improves mood
but continued use is associated with a continuation of
symptoms of anxiety and depression [61] and with an in-
creased risk of developing cannabis dependence [30]. The
latter is indicated by the large proportion of medical
cannabis patients using Californian dispensaries who have
been daily cannabis users since adolescence. 
It is instructive to compare the characteristics of Cal-
ifornian medical cannabis users with those in the Nether-
lands, where recreational cannabis use by adults has been
decriminalized since the 1970s [63], and hence, recre-
ational users have no need to access medical cannabis. The
Netherlands legislated to allow the medical use of
cannabis in 2003, and cannabis is provided in a form suit-
able for oral use at pharmacies on the prescription of a
physician [62]. The estimated annual use of medical
cannabis in the Netherlands has varied between 8 and 10
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per 100,000 between 2005 and 2010 [64] compared with
estimated rates of 7,000 per 100,000 in California. Dutch
medical cannabis users were much older than their Cali-
fornian counterparts (55.6 years versus 40.7 years), and
used lower daily doses (0.68 g versus 2.4-3.8 g). The other
drugs that these patients were prescribed suggest that they
more often used cannabis to treat chronic pain rather than
symptoms of AIDS and cancer. 
SHOULD WE LEGALIZE CANNABIS?
Grinspoon and Bakalar [2] have argued that the sim-
plest way to enable patients to use cannabis for medical
purposes would be to legalize all adult use of cannabis.
This would enable patients who wanted to use cannabis
for medical purposes to do so at their own risk and with-
out needing a medical prescription. It would also be legal
to grow, supply, and purchase cannabis. Legalization
would sever the Gordian knot of regulatory issues that sur-
round cannabis prescription programs and medical mari-
juana initiatives. 
Until very recently, the major political and legal ob-
stacle to legalization has been the United Nations Single
Convention, which prohibits the nonmedical use of
cannabis [63]. This policy has consistently enjoyed ma-
jority public support in most developed countries [63] but
this recently changed in the United States with the pas-
sage of citizen-initiated referenda that legalized recre-
ational cannabis use in Colorado and Washington in 2012
and Alaska and Oregon in 2014 [65]. Colorado and Wash-
ington implemented legal cannabis markets for recre-
ational use in 2013 and 2014, respectively [66,67].
The fact that cannabis use has been legalized in
these U.S. states creates an interesting issue for the reg-
ulation of medical cannabis use. Colorado’s regulations
allow medical cannabis users to pay a lower rate of tax
on their cannabis than recreational users. This has cre-
ated an incentive for tax evasion. Recreational users ap-
pear to have recognized this, judging by a large increase
in the numbers of persons registering to use cannabis for
medical reasons in Colorado after the passage of
cannabis legalization [68]. This policy choice will pre-
vent Colorado from receiving the large tax income wind-
fall that was predicted by advocates of legalization when
campaigning for voters to support cannabis legalization
[69,70]. 
One could argue that medical cannabis use should
only be given a tax advantage for medical indications in
which there is evidence of efficacy. But this would require
a system of medical approval and registration that could
be expensive to run, creating another regulatory expense
that cannabis legalization was supposed to remove. It
would be arguably simpler and better policy if medical
users paid the same price for their cannabis as everyone
else. This price will be considerably cheaper under a legal
regime than it has been in dispensaries operating under a
nominal policy of prohibition [71]. 
SUMMING UP: MEDICAL MARIJUANA 
CONUNDRUMS
Controlled clinical trials indicate that cannabinoids
have some efficacy in controlling emesis in cancer pa-
tients, in stimulating appetite in AIDS patients, and in re-
lieving pain and spasticity. There are, however, now much
more effective drugs available for most of these indica-
tions. If cannabinoids have a medical role in these condi-
tions, it is as second- or third-line treatments or as
adjunctive treatments.
Pharmaceutical synthetic cannabinoids have been ap-
proved for medical use (e.g., dronabinol), but they have
not been widely used because patients find it difficult to
achieve therapeutic doses. These drugs have not been very
profitable for the companies that produced them. The
small market for cannabinoids, the lack of profitability,
and the regulatory costs and burdens of their clinical use
are major disincentives to the development of more ef-
fective cannabinoids [7]. 
A pharmaceutical cannabis extract, Sativex, has been
approved for medical use in multiple sclerosis and neuro-
pathic pain in a number of countries but not yet the United
States. It has shown modest efficacy in clinical trials in
controlling these symptoms, but regulators in some coun-
tries have found the evidence unconvincing. It remains to
be seen if Sativex proves more acceptable to patients than
dronabinol and nabilone. 
Medical marijuana advocates in the United States
have used referenda to circumvent the pharmaceutical reg-
ulatory system and enable patients to smoke cannabis.
These initiatives have created problems for physicians
who have been reluctant to prescribe cannabis because of
uncertainty about clinical indications and fears of being
legally liable for any harm that patients experience. 
Securing a legal supply of cannabis has been a prob-
lem for medical cannabis users. Some governments have
allowed cannabis dispensaries to provide approved pa-
tients with access to cannabis. Even under these systems,
physicians have been reluctant to prescribe cannabis for
medico-legal reasons. 
In some U.S. states, medical cannabis schemes have
been used as a “Trojan horse” for the legalization of recre-
ational cannabis use. This outcome has been facilitated by
state laws that 1) define the criteria for medical cannabis
use very broadly; 2) allow the decisions as to whether a
patient meets these criteria to be made by doctors and pa-
tients, without any independent scrutiny; and 3) allow for-
profit businesses to supply cannabis to approved patients.
This policy has arguably facilitated the legalization of
cannabis in Colorado and Washington State, which have
enacted these types of medical cannabis laws. If govern-
ments want to legalize cannabis, it would be better, on the
grounds of honesty and transparency, to do this after an
informed public debate about the pros and cons of legal-
ization, rather than by stealth in the guise of providing
medical access to cannabis. This would involve a consid-
eration of both the potential benefits (e.g., reduced law en-
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forcement costs, elimination of criminalizing cannabis
users, taxation of cannabis products) and potential costs
of legalization (e.g., increased cannabis users and
cannabis-related harm) [63,71].
A better-informed policy toward the medical use of
cannabinoids requires more evidence. First, we need clin-
ical trials of the safety and efficacy of CBD and other
cannabinoids in treating intractable epilepsy and chronic
pain. In the interim, governments can allow medical ne-
cessity as a defense against criminal prosecution for pa-
tients with these conditions who use cannabis. The
uncertainties about the potential adverse effects of sus-
tained use of cannabis for medical use need to be clearly
communicated to patients considering their use. Second,
we need long-term follow-up studies of patients who use
cannabis preparations and medical cannabinoids over pe-
riods of years to assess the risks of developing cannabis
dependence, exacerbating cardiovascular disease, precip-
itating psychotic disorders, and developing cancer [5,37]. 
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